"Multiple myeloma" is gradually becoming a chronic disease

"Multiple myeloma" is gradually becoming a chronic disease

October 30, 2017 Source: People's Network

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

When it comes to blood tumors or "blood cancer", people usually think of leukemia. In fact, there is a common blood cancer called "multiple myeloma", which is caused by malignant cancer of the plasma cells in the bone marrow, and the incidence rate is second only to lymphoma.

The author learned from the First Affiliated Hospital of Sun Yat-sen University that Professor Li Juan of the Department of Hematology of the hospital took the lead in adopting the overall treatment strategy of “Induction of New Drugs-Autologous Hematopoietic Stem Cell Transplantation-Maintenance Treatment”, and the median of patients with multiple myeloma. The survival period has been extended to 95.4 months. Many patients have survived for more than ten years, and multiple myeloma has gradually changed from a malignant tumor to a chronic disease.

Li Juan said that multiple myeloma occurs mostly in middle-aged and elderly people. The cause of the disease is still unclear, and the degree of malignancy is high. The patient's previous survival period is only 33 months. Nowadays, there are a variety of new drugs for the treatment of multiple myeloma, including “reaction stop” (thalidomide), “Ruifumei” (lenalidomide), and “Wanxi” (boron). Proteome inhibitors such as tilzomib.

Since 2006, Li Juan has proposed and implemented an overall treatment strategy for “induction of new drugs – autologous hematopoietic stem cell transplantation – maintenance therapy” earlier in China. This type of treatment is generally performed on the patient for 4 months of induction therapy, minimizing malignant cells in the bone marrow, and then performing autologous stem cell transplantation. After successful transplantation, continue to use the drug for maintenance treatment.

As of now, hundreds of patients with myeloma have received this treatment, and their median survival has been nearly tripled to 95.4 months. Among them, many patients have survived for 11 years without disease, and no signs of recurrence.

Pain Relief Patch For Neck Shoulder,Lower Back And Leg

Pain Relief Patch for neck shoulder, lower back and leg.
[Name] Medical Cold Patch
[Package Dimension] 10cm×12cm 2pieces/box
The pain relief patch is composed of three layers, namely, backing lining, middle gel and protective film. It is free from pharmacological, immunological or metabolic ingredients.
[Scope of Application] For cold physiotherapy, closed soft tissue only.
[Indications]
The patches give fast acting pain relief for strains, sprains, cramp, bruises, swollen areas or joint stiffness.
[How To Use a Patch]
Tear off the packaging bag and remove the patch. Remove the protective film and apply the patch on the skin. One piece, one time. The curing effect of each piece can last for 8-12 hours.
[Attention]
Do not apply the patch on the problematic skin, such as wounds, eczema, dermatitis,or in the eyes. People allergic to herbs and the pregnant are advised not to use the medication. If swelling or irritation occurs, please stop using and if any of these effects persist or worsen.notify your doctor or pharmacist promptly. Children using the patch must be supervised by adults.
[Storage Conditions]
Store below 30c in a dry place away from heat and direct sunlight.







Pain Relief Patch,Pain Relief Pad,Pain Relief Plaster,Neck Pain Relief Patch,Back Pain Relief Pacth

Shandong XiJieYiTong International Trade Co.,Ltd. , https://www.xijieyitongpatches.com